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Abstract
Introduction: Visfatin is an adipokine secreted by visceral adipose tissue with
insulin-mimetic properties. Higher circulating visfatin levels were reported in
type 2 diabetes. The aim of this study was to analyse circulating visfatin and
insulin levels and the visfatin/insulin ratio in obese women with and without
metabolic syndrome (MetS). 
Material and methods: The study involved 92 obese women. Subjects were diag-
nosed with MetS according to IDF 2005 criteria. The MetS group consisted of
71 subjects (age: 52.8 ±9.4 years, body mass index [BMI]: 39.1 ±5.6 kg/m2, waist
circumference: 109.6 ±11.4 cm and fat mass: 52.0 ±12.8 kg) while the non-MetS
group consisted of 21 subjects (age: 51.7 ±9.5 years, BMI: 36.3 ±5.2 kg/m2, waist
circumference: 104.7 ±11.0 cm and fat mass: 45.2 ±10.7 kg). In addition to anthro-
pometric measurements and assessment of serum glucose and lipids, plasma
concentrations of visfatin were estimated by enzyme-linked immunosorbent
assay (ELISA) and of insulin by radioimmunoassay (RIA). Homeostatic model
assessment insulin resistance (HOMA-IR) and visfatin/insulin ratio were calcu-
lated.
Results: In the MetS group significantly higher (p < 0.01) plasma concentrations
of insulin and HOMA-IR values but similar visfatin levels were observed than in
the non-MetS group. As a consequence of the significantly higher plasma insulin
concentration the visfatin/insulin ratio was significantly lower in the MetS group
(p < 0.05). The visfatin/insulin ratio correlated inversely with anthropometric
parameters such as body mass, BMI, body fat and waist circumference (r = –0.41,
p = 0.0003; r = –0.42, p = 0.0002; r = –0.29, p = 0.01; r = –0.23, p = 0.04, respec-
tively).
Conclusions: We conclude that the visfatin/insulin ratio declining with increas-
ing visceral obesity may predispose to the development of insulin resistance.
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Introduction 
Visfatin is an adipokine predominantly secreted by visceral adipose tis-
sue and its release is upregulated in obese animals and humans [1, 2]. Its
expression in visceral and subcutaneous adipose tissue is inversely relat-
ed to body mass index (BMI) changes. In normal weight, insulin sensitive
subjects, visfatin is predominantly produced by subcutaneous adipose 
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tissue [3]. In contrast, in the obese subjects, high
synthesis of visfatin by macrophages in visceral adi-
pose tissue was ob  served [3-6].
Visfatin may act as an autocrine, paracrine and
endocrine mediator and participate in the regula-
tion of a variety of physiological functions including
cell proliferation, synthesis of nicotinamide mono-
and dinucleotide and glucose homeostasis [7]. 
Experimental studies have revealed that visfatin
has insulin-mimetic properties. This adipokine binds
to the insulin receptor at a site distinct from insulin.
By this mechanism visfatin reduces glucose release
from hepatocytes and stimulates glucose utiliza-
tion in adipocytes and myocytes [1].
Our recent study [8], similarly to others previ-
ously published [2, 9, 10], reported an increased cir-
culating visfatin level in the obese subjects. More-
over, in type 2 diabetic patients increased
circulating visfatin levels have also been observed
[11-13]. Based on these results it was suggested that
the increasing visfatin level may serve as a com-
pensation for the impairment of insulin action [6].
However, data concerning the association between
circulating levels of visfatin and insulin resistance
are inconsistent [11-15].
The pathogenesis of insulin resistance in humans
is complex. Therefore, a simple link between circu-
lating level of visfatin and insulin resistance is 
difficult to establish. As previously mentioned, vis-
fatin has insulin-mimetic properties. However, 
visfatin also stimulates production and release of
proinflammatory cytokines by monocytes and
macrophages, such as tumour necrosis factor-α
(TNF-α) and interleukin-6 (IL-6). These cytokines
are involved in the pathogenesis of insulin resist-
ance [6]. Therefore, an increased visfatin level in
the obese may also indirectly participate in the
development of insulin resistance. 
It was also found that visfatin is highly expressed
in lipid-loaded macrophages in atherosclerotic
lesions, particularly in plaques of symptomatic
patients [16].
To shed more light on the putative role of vis-
fatin in the development of insulin resistance in
MetS, we measured the circulating levels of vis-
fatin and insulin in a subset of obese subjects
matching or not matching the International Dia-
betes Federation (IDF) 2005 criteria of MetS. We
hypothesised that MetS is characterized by an
imbalance between circulating visfatin and insulin
levels. 
Material and methods 
Ninety-two obese women with stable weight
during the last 3 months were included in the study.
Their obesity had lasted for at least some years.
Patients with weight loss or gain above 3 kg during
6 months, chronic inflammatory diseases, type 2
diabetes, treated hypertension, acute and gas-
trointestinal diseases, pregnancy, any medication,
drug abuse, smoking and consumption of more
than 2 alcoholic drinks per week were excluded.
The study was approved by the Ethics Committee
of the Medical University of Silesia. All subjects
gave their informed consent for participation in
the study.
Seventy-one subjects fulfiled the IDF 2005 diag-
nostic criteria of MetS (MetS group), while 21 oth-
ers did not (non-MetS group). Characteristics of
study groups are presented in Table I.
Anthropometric measurements (weight, height,
waist circumference) and blood pressure measure-
ments were performed in all subjects. The BMI was
calculated according to the standard formula. Body
composition was assessed by the bioimpedance
method using a Bodystat 1500 analyzer (Douglas,
Isle of Man).
Venous blood samples were withdrawn in the
morning between 8.00 a.m. and 9.00 a.m., after
overnight fasting (16 h). The blood samples were
collected according to the recommendations of kit
manufacturers. Serum and plasma samples were
stored frozen at –70°C.
Parameter MetS  Non-MetS  Value of p
(n = 71) (n = 21)
Age [years] 52.8 ±9.4 51.7 ±9.5 NS
Weight [kg] 100.9 ±15.0 94.3 ±13.9 NS
BMI [kg/m2] 39.1 ±5.6 36.3 ±5.2 NS
Body fat [kg] 52.0 ±12.8 45.2 ±10.7 < 0.05
Body fat [%] 50.8 ±6.3 47.4 ±6.9 NS
Fat-free mass [kg] 48.9 ±5.8 49.1 ±9.0 NS
Fat-free mass [%] 49.2 ±6.5 52.6 ±6.7 NS
Waist  109.6 ±11.4 104.7 ±11.0 NS
circumference [cm]
Systolic blood  144.7 ±20.8 131.9 ±13.6 < 0.05
pressure [mm Hg]
Diastolic blood  86.8 ±11.9 79.7 ±10.4 NS
pressure [mm Hg]
Glucose [mg/dl] 114 ±27 89 ±9 < 0.005
Total cholesterol  237 ±51 205 ±44 < 0.05
[mg/dl]
LDL cholesterol  160 ±59 127 ±44 NS
[mg/dl]
HDL cholesterol  46 ±13 60 ±15 < 0.01
[mg/dl]
Triglycerides [mg/dl] 154 ±71 86 ±25 < 0.005
Table I. Characteristics of obese women fulfilling (MS)
or not fulfilling (non-MS) the diagnostic criteria of
metabolic syndrome (MS)
BMI – body mass index, LDL – low density lipoprotein, HDL – high den-
sity lipoprotein
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Laboratory procedures
Plasma glucose, triglycerides and total choles-
terol and its LDL (low density lipoproteins) and HDL
(high density lipoproteins) fractions were measured
by colorimetric methods using a commercially avail-
able kit (Roche, Switzerland). 
Serum insulin concentration was assessed by
radioimmunoassay (DPC Diagnostic Products Cor-
poration, Los Angeles, USA) with a lower limit of
sensitivity of 1.2 μIU/ml and intra- and inter-assay
coefficients of variations of 5.2% and 5.8%, respec-
tively. The HOMA-IR index was calculated with the
standard formula: HOMA-IR = fasting concentra-
tion of insulin [μIU/ml] × fasting concentration of
glucose [mmol/l]/22.5 (normal ratio < 2.77).
The plasma concentration of visfatin was esti-
mated by a commercially available ELISA kit from
Phoenix Pharmaceuticals (Burlingame, USA) with
the lower limit of sensitivity of 2.63 ng/ml and intra-
and inter-assay coefficients of variations of 5.2 and
5.8% respectively. 
The visfatin/insulin ratio was calculated for plas-
ma insulin and visfatin concentrations expressed
in pmol/l (Table II). 
Statistical analysis 
All statistical analyses were performed using Sta-
tistica 8.0 software (Statsoft Poland, Krakow)
Results are presented as means ± SD. The Mann-
Whitney U test (two-tailed) was used for group
comparisons. The univariate correlation coefficients
were calculated according to Spearman. A p < 0.05
was considered as signi  ficant.
Results
Both groups of obese women, MetS and non-
MetS, were of similar age, and had comparable
body mass, BMI, waist circumference and fat free
mass (Table I). Only the content of fat mass
expressed in kg was higher in the MetS than in the
non-MetS group (Table I). 
As expected, serum concentrations of total cho-
lesterol, triglycerides, glucose and insulin and
HOMA-IR value were higher and concentration of
HDL cholesterol was lower in the MetS than in the
non-MetS group (Tables I and II). 
Plasma concentrations of visfatin were only
slightly (by 12.8%), not significantly higher in the
MetS than in the non-MetS group. As a conse-
quence of the significantly higher plasma insulin
concentration the visfatin/insulin ratio was also sig-
nificantly lower in the MetS group (Table II). 
There was a significant positive correlation
between concentrations of visfatin and triglycerides,
insulin or HOMA-IR values (r = 0.45, p = 0.04; 
r = 0.53, p = 0.01; r = 0.53, p = 0.01, respectively) in
the non-MetS but not in the MetS group. 
A significant negative correlation between vis-
fatin/insulin ratio and body mass (r = –0.41; 
p = 0.0003) (Figure 1), BMI (r = –0.42; p = 0.0002)
(Figure 2), fat mass (r = –0.29; p = 0.01) (Figure 3)
and waist circumference (r = –0.23; p = 0.04) 
(Figure 4) only in the MetS group was found.
Parameter MetS  Non-MetS  Value of p
Insulin [μIU/ml] 16.6 ±10.9 8.8 ±4.6 0.01
HOMA-IR 5.5 ±4.3 2.0 ±1.2 0.0001
Visfatin [ng/ml] 33.6 ±12.6 29.8 ±8.7 NS
Visfatin/insulin ratio 9.3 ±7.3 12.5 ±4.9 0.005
[pmol/l]
Table II. Plasma concentrations of visfatin and insulin
and their ratios and HOMA-IR in obese women ful-
filling (MS) or not fulfilling (non-MS) the diagnostic
criteria of metabolic syndrome (MetS) 
HOMA-IR – homeostasis model assessment insulin resistance 
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Figure 1. Correlation between body mass and visfatin
to insulin ratio
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Figure 2. Correlation between BMI and visfatin to
insulin ratio 
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There was no correlation between visfatin/
insulin ratio and serum concentrations of glucose
and lipids in both analysed groups.
Discussion
Our results demonstrate that plasma concen-
tration of visfatin increases along with rising insulin
resistance, but the increase is less pronounced than
that of insulin.
An association between insulin resistance and
visfatin level was not established. Our previously
published study [8] revealed an increased plasma
visfatin level in obese women, and a significant pos-
itive correlation between plasma glucose (but not
insulin) and visfatin concentrations in this group.
Serum concentrations of insulin correlated positively
with those of visfatin only in normal weight sub-
jects. Therefore, we hypothesized that an increased
circulating visfatin level in the obese may be one of
the compensatory mechanisms at the early stage
of the development of insulin resistance. The report-
ed positive correlation between plasma visfatin lev-
els and HOMA-IR supports our hypothesis [13]. Chen
et al. [13] proposed that elevated visfatin levels in
subjects with type 2 diabetes mellitus may reflect
the impairment of visfatin signalling in target tis-
sues (visfatin resistance) or the response to hyper-
glycaemia or to hyperinsulinaemia. However, the
observed associations between circulating visfatin
and insulin levels or HOMA-IR values only in the
non-MetS group, and only slightly (not significant-
ly) higher visfatin levels despite markedly increased
concentrations of insulin and HOMA-IR values in the
MetS group, seem to confirm our theory rather than
that of Chen et al. [13]. 
As insulin resistance and visfatin release from
visceral adipose tissue increase with rising adipos-
ity [3, 4], we should expect an association between
BMI or other anthropometric measurements with
circulating visfatin levels. However, the reported
data of the associations between BMI and plasma
visfatin level are inconsistent. Some [2,3], but not
all [5] studies have shown significant positive cor-
relations between these parameters. In the pres-
ent study we did not observe any correlation
between anthropometric parameters and plasma
visfatin levels either in all study subjects or in the
study groups.
Perhaps the proportion of the circulating visfatin
and insulin molecules, expressed as the vis-
fatin/insulin ratio, is more important than visfatin
alone for prevention of the development of insulin
resistance and MetS in the obese. Decreased vis-
fatin/insulin ratio in MetS and the negative corre-
lation between visfatin/insulin ratio and anthropo-
metric parameters correspond to the insulin
resistance in the obese with MetS. This may sug-
gest that the increase of visfatin production in
obese subjects with MetS is insufficient to prevent
the development of insulin resistance. To the best
of our knowledge, the only study that has assessed
this issue was a paper by Panidis et al. [6]. In this
study the visfatin/insulin ratio was analysed in nor-
mal weight women with polycystic ovary syndrome
and healthy women with normal weight, over-
weight and obesity without concomitant diseases.
The results presented in this study showed a sig-
nificantly higher visfatin/insulin ratio in non-MetS
than in MetS obese women. 
Our study has several limitations including the
cross-sectional study design, the small number of
non-MetS subjects and the method of insulin resist-
ance assessment. We did not apply the reference
method of insulin resistance measurement, i.e.
metabolic clamp technique.
In conclusion, we conclude that the visfatin/
insulin ratio declining with increasing visceral obe-
sity may predispose to the development of insulin
resistance.
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Figure 3. Correlation between fat mass and visfatin
to insulin ratio 
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Figure 4. Correlation between waist circumference
and visfatin to insulin ratio
r = –0.23, p = 0.04
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